Zobrazeno 1 - 10
of 1 191
pro vyhledávání: '"Landon L"'
Autor:
Landon L. Chan, Stephen L. Chan
Publikováno v:
Клинический разбор в общей медицине, Vol 5, Iss 7, Pp 24-36 (2024)
Emergence of multi-targeted kinase inhibitors (MTIs) and immune checkpoint inhibitors (ICI) have changed the landscape of management in hepatocellular carcinoma (HCC). Combination therapy involving ICI has superseded sorafenib as the first-line treat
Externí odkaz:
https://doaj.org/article/6018f6404fd44328a5aec940740119bd
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Adoption of immunotherapy has completely transformed the treatment landscape of cancer. Patients with advanced cancer treated with immunotherapy may benefit from durable tumor response and long-term survival. The most widely used immunotherapy in sol
Externí odkaz:
https://doaj.org/article/9bc612db785f42f3ab18cd6540131412
Autor:
Moore, Landon L.1,2 (AUTHOR) landon-moore@ouhsc.edu, Qu, Dongfeng1 (AUTHOR) dongfeng-qu@ouhsc.edu, Sureban, Sripathi1,2 (AUTHOR) mssripathi@gmail.com, Mitchell, Stephanie1 (AUTHOR) stephanie-mitchell@ouhsc.edu, Pitts, Kamille1,2 (AUTHOR) kamille-pitts@ouhsc.edu, Cooper, Nasya3 (AUTHOR) nasya.cooper@langston.edu, Fazili, Javid1 (AUTHOR) javid-fazili@ouhsc.edu, Harty, Richard1 (AUTHOR) richard-harty@ouhsc.edu, Oseini, Abdul1 (AUTHOR) abdul-oseini@ouhsc.edu, Ding, Kai4 (AUTHOR) kai-ding@ouhsc.edu, Bronze, Michael1 (AUTHOR) michael-bronze@ouhsc.edu, Houchen, Courtney W.1,2 (AUTHOR) courtney-houchen@ouhsc.edu
Publikováno v:
International Journal of Molecular Sciences. Jun2024, Vol. 25 Issue 12, p6481. 17p.
Autor:
Chan, Stephen L., Ryoo, Baek-Yeol, Mo, Frankie, Chan, Landon L., Cheon, Jaekyung, Li, Leung, Wong, Kwan H., Yim, Nicole, Kim, Hyeyeong, Yoo, Changhoon
Publikováno v:
In Journal of Hepatology August 2024 81(2):258-264
Autor:
Saw, Stephanie P.L., Low, Yi Fen, Lai, Gillianne G.Y., Chan, Landon L., Wong, Wesley K.Y., Tsui, Giselle, Chen, Olivia H., Seet, Amanda O.L., Tan, Wei Chong, Tan, Aaron C., Chan, Johan W.K., Teh, Yi Lin, Tan, Wan-Ling, Ng, Quan Sing, Ang, Mei-Kim, Kanesvaran, Ravindran, Lim, Darren W.T., Tan, Daniel S.W., Mok, Tony S.K., Li, Molly S.C.
Publikováno v:
In Lung Cancer July 2024 193
Autor:
Molly S.C. Li, M.B.B.S., Kirsty W.C. Lee, MBChB, Kevin K.S. Mok, MBChB, Herbert H.F. Loong, M.B.B.S., K.C. Lam, MBChB, Florence S.T. Mok, M.B.B.S., Landon L. Chan, MBChB, Y.M. Lau, M.B.B.S., K.P. Chan, MBChB, Joyce T.Y. Ng, MBChB, Wesley K.Y. Wong, M.B.B.S., Benjamin H.W. Lam, M.B.B.S., Allen C.C. Chen, BM, Matthew M.P. Lee, MBChB, Olivia H. Chen, MD, PhD, Tony S.K. Mok, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100648- (2024)
Introduction: Interstitial lung disease (ILD) is the most frequent cause of drug-related mortality from EGFR tyrosine kinase inhibitors (TKIs). Yet, for patients with symptomatic osimertinib-induced ILD, the risk of recurrent ILD associated with EGFR
Externí odkaz:
https://doaj.org/article/3e7352949ccd4e5d8d2933a594642014
Autor:
Landon L. Chan, Stephen L. Chan
Publikováno v:
Clinical and Molecular Hepatology, Vol 29, Iss 4, Pp 909-923 (2023)
Emergence of multi-targeted kinase inhibitors (MTIs) and immune checkpoint inhibitors (ICI) have changed the landscape of management in hepatocellular carcinoma (HCC). Combination therapy involving ICI has superseded sorafenib as the first-line treat
Externí odkaz:
https://doaj.org/article/8d62e67bb0b442e086f1983cd638e24c
Publikováno v:
In The Journal of Liquid Biopsy March 2024 3
Publikováno v:
The Journal of Liquid Biopsy, Vol 3, Iss , Pp 100131- (2024)
Molecular profiling is essential for treatment of patients with advanced non-small cell lung cancer. Extensive evidence supports the clinical application of liquid biopsy in molecular profiling and thus has been incorporated into multiple internation
Externí odkaz:
https://doaj.org/article/ea7cb5082ad1433a842e674d1fbbba18